One of the proteins on the virus – located on the characteristic COVID spike – has a component called the receptor-binding domain, or RBD, which is its “Achilles heel.” That is, he said, antibodies against this part of the virus have the potential to the neutralize the virus.
As the race for a COVID-19 vaccine intensifies, health care officials are reminding the public not to forget another important vaccine this fall: the flu shot. Flu season in the U.S. technically began in September, with illnesses expected to peak in December and February, according to the Centers for Disease Control (CDC). Less than half of Americans received a flu vaccine during the 2019-2020 flu season, and a staggering 405,000 hospitalizations and 22,000 deaths were attributed to influenza.
New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.
Edward Jones-Lopez, MD, MS, a Keck Medicine of USC infectious diseases expert and investigator of one of the Operation Warp Speed vaccine clinical trials, answers the questions on everyone’s mind.
Two Rutgers New Jersey Medical School pediatricians discuss the importance of keeping children and adults up to date with immunizations during the coronavirus crisis.
An immunology researcher in Canada has found a simple solution to prevent infections in children with lactic acidosis: get them vaccinated.
A research team from the City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), the Barcelona Institute for Global Health (ISGlobal), the Vaccine Confidence Project at the London School of Hygiene and Tropical Medicine (LSHTM), and Georgetown University Law School announced today that Nature Medicine has published their research revealing potential global hesitancy to accept a COVID-19 vaccine.
If an initial COVID-19 vaccine is about as effective as a flu shot, uptake by the American public may fall far short of the 70% level needed to achieve herd immunity, new Cornell research suggests.
The National Foundation for Infectious Diseases (NFID) issued a new Call to Action report detailing the risks of co-infection with influenza (flu) and COVID-19 in adults with chronic health conditions, and the importance of flu vaccination during the 2020-2021 season.
University of Chicago Medicine infectious diseases expert Dr. Allison Bartlett explains what to know to stay safe this winter from both influenza and COVID-19.
A new article by Columbia Mailman School researchers Jeffrey Shaman and Marta Galanti explores the potential for the COVID-19 virus to become endemic, a regular feature producing recurring outbreaks in humans.
Researchers with the U.S. Army Futures Command are part of a team that tested alternative ways to measure COVID-19 antibody levels, resulting in a process that is faster, easier and less expensive to use on a large scale.
The COVID-19 pandemic will remain the dominant topic for Americans in nearly every aspect of their lives in 2021, according to a survey in the USC Center for Public Relations’ annual Relevance Report. When asked about news they will consume, 44% of Americans say the COVID-19 vaccine will be the topic they are most interested in hearing and reading about within the next year. However, despite the challenges faced in 2020, Americans remain hopeful about the future, with 37% choosing “fingers crossed” as the emoji that best expresses their feelings about the new year — more than twice the number of respondents who said they were worried.
People who have recovered from COVID-19, and their close contacts, could hold the key to understanding how immunity to the disease develops, how long it lasts and what happens when immunity is lost.
A team of researchers at the University of Chicago have developed a self-assembling nanoparticle to create a toolbox for treating infections such as Toxoplasma gondii, a serious parasitic infection.
In a new COVID-19 clinical trial, Stuart Cohen at UC Davis Health evaluates the efficacy, safety and tolerability of monoclonal antibody combination in adults exposed to patients with COVID-19. It is the same antibody drug given to President Trump to treat his COVID-19.
New research in Clinical and Translational Immunology, provides a clearer picture of the protective antibodies induced by SARS-CoV-2 and their role in serious illness and what’s needed for full protection.
A COVID-19 vaccine candidate that underwent extensive preclinical testing this spring and summer shows potent preclinical immune responses — including several that distinguish it from other COVID-19 vaccine approaches — according to a preprint deposited in the BioRxiv repository.
Vaccines currently being developed for Covid-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologist.
Rutgers medical schools' Dean discusses the importance of Black and Latinx representation in clinical trial studies and the critical steps the medical community can take in rebuilding the trust in minority communities by more transparency and continuous education
Media invited to live Q&A on Oct 7th, 2pm EDT
While researchers around the world race to develop an effective and safe COVID-19 vaccine, a team from the San Diego Supercomputer Center (SDSC) at UC San Diego contributed to a study led by Vanderbilt Vaccine Center of Vanderbilt University Medical Center (VUMC) on T cell receptors, which play a vital role in alerting the adaptive immune system to mount an attack on invading foreign pathogens including the Coronavirus SARS-CoV-2.
Researchers at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory are making progress on several fronts in the battle against COVID-19, the global pandemic sparked by the emergence of a novel coronavirus late last year. This work is part of a worldwide effort to understand the virus and the factors that affect its spread with the aim of devising treatments and other mitigation strategies.
With funding from the Coronavirus Aid, Relief and Economic Security (CARES) Act, Lawrence Livermore National Laboratory, chipmaker AMD and information technology company Supermicro have upgraded the supercomputing cluster Corona, providing additional resources to scientists for COVID-19 drug discovery and vaccine research
ORNL story tips: Remote population counting, slowing corrosion and turning down the heat
A coalition of 11 academic institutions and their community partners across California has received a $4.1 million grant from the NIH for a statewide community-engaged approach to addressing COVID-19 among populations that have been disproportionately affected by the pandemic.
A study to determine the effectiveness of the drug IP-00 in producing immune responses as a booster for the eventual vaccine for COVID-19 is being conducted by researchers in the Biophotonics & ImmunoEngineering Laboratory, led by Professor Wei R. Chen in the Stephenson School of Biomedical Engineering at the University of Oklahoma. The OU researchers are collaborating with Immunophotonics, Inc., St. Louis, Missouri, on the study.
A Rutgers infectious disease expert explains why the flu vaccination is more important than ever this year
Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead's new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead's first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.
This year's flu season won't be like any other, due to the ongoing COVID-19 (coronavirus) pandemic. Because the flu and COVID-19 can present in similar ways, anyone who experiences overlapping symptoms of the two viruses may have to assume it's COVID-19 unless testing is performed, according to Cedars-Sinai experts.
SEATTLE – Oct. 1, 2020 – Below are summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.And if you’re looking for sources for October’s Breast Cancer Awareness Month, please see our breast cancer page for a list of projects, experts and the latest breast cancer news.
This month's issue of AJPH tackles health misinformation that has run rampant on social media during the COVID-19 pandemic.
The role of bots in spreading vaccine-critical information on Twitter is limited, and rarely cross paths with active Twitter users, finds study led by University of Sydney.
Anti-vaccination discourse on Facebook increased in volume over the last decade, coalescing around the argument that refusing to vaccinate is a civil right, according to a study published today in the American Journal of Public Health.
UC San Diego Health will be a test site for a third, major Phase III clinical trial to assess a vaccine candidate for the novel coronavirus that causes COVID-19. Sponsored by Janssen Pharmaceuticals, the trial will recruit up to 60,000 participants at sites in the United States and worldwide.
With cold and flu season underway, plus the ongoing COVID-19 pandemic, infectious disease specialist Jeffrey Bender, MD, shares how to tell the difference between the three illnesses, and the most important thing parents can do to keep children safe.
Researchers apply a novel reverse genetics approach to create recombinant SARS-CoV-2San Antonio, Texas (October 1, 2020) – Researchers at Texas Biomedical Research Institute (Texas Biomed) recently published findings from an innovative SARS-CoV-2 study that will assist in the development of new vaccines and antivirals for COVID-19.
Biomarkers using mass cytometry can assess patient response to an emerging vaccine for a specific pediatric brain tumor, according to a recent multi-center study published in the Journal of Clinical Investigation.
A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right